Browse EV MemProt Atlas
Supporting publications (n)
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| SIDT2 | Q8NBJ9 | SID1 transmembrane family member 2 | Predicted intracellular proteinsPredicted membrane proteinsTransporters | 10 | Fusion and delivery mediationMetabolism mediation | 2 | 0.25 | |||
| SL9A7 | Q96T83 | Sodium/hydrogen exchanger 7 (Na(+)/H(+) exchanger 7) (NHE-7) (Solute carrier family 9 member 7) | Disease related genesHuman disease related genesMetabolic proteins | 14 | Clinical-translation mediationFusion and delivery mediation | 2 | 0.25 | |||
| T106B | Q9NUM4 | Transmembrane protein 106B | Disease related genesHuman disease related genesPotential drug targets | 1 | Fusion and delivery mediation | 2 | 0.25 | |||
| TM63C | Q9P1W3 | Osmosensitive cation channel TMEM63C (Calcium permeable stress-gated cation channel 1) (Transmembrane protein 63C) (hTMEM63C) | Disease related genesHuman disease related genesPotential drug targets | 11 | Other mediation | 2 | 0.25 | |||
| TSN1 | O60635 | Tetraspanin-1 (Tspan-1) (Tetraspan NET-1) (Tetraspanin TM4-C) | Predicted membrane proteins | 4 | Fusion and delivery mediation | 2 | 0.25 | |||
| TTYH3 | Q9C0H2 | Protein tweety homolog 3 (hTTY3) (Volume-regulated anion channel subunit TTYH3) | Predicted membrane proteinsTransporters | 5 | Fusion and delivery mediation | 2 | 0.25 | |||
| 5HT1D | P28221 | 5-hydroxytryptamine receptor 1D (5-HT-1D) (5-HT1D) (Serotonin 1D alpha receptor) (5-HT-1D-alpha) (Serotonin receptor 1D) | 7 | Alzheimer diseaseDementiaDepression | Clinical-translation mediationReceptor-signaling mediation | 1 | 0.25 | |||
| ABCA5 | Q8WWZ7 | Cholesterol transporter ABCA5 (EC 7.6.2.-) (ATP-binding cassette sub-family A member 5) | Human disease related genesPredicted intracellular proteinsPredicted membrane proteins | 15 | Fusion and delivery mediation | 1 | 0.25 | |||
| ADA17 | P78536 | Disintegrin and metalloproteinase domain-containing protein 17 (ADAM 17) (EC 3.4.24.86) (Snake venom-like protease) (TNF-alpha convertase) (TNF-alpha-converting enzyme) (CD antigen CD156b) | CD markersDisease related genesEnzymes | 1 | Breast cancerChronic obstructive pulmonary diseaseIndeterminate colitis | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 1 | 0.25 | ||
| ADA2A | P08913 | Alpha-2A adrenergic receptor (Alpha-2 adrenergic receptor subtype C10) (Alpha-2A adrenoreceptor) (Alpha-2A adrenoceptor) (Alpha-2AAR) | 7 | Alzheimer diseaseAttention deficit hyperactivity disorderDementia | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.25 | |||
| AGTR1 | P30556 | Type-1 angiotensin II receptor (AT1AR) (AT1BR) (Angiotensin II type-1 receptor) (AT1 receptor) | Disease related genesFDA approved drug targetsG-protein coupled receptors | 7 | Alzheimer diseaseArteries/arterioles disorderEssential hypertension | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.25 | ||
| AGTR2 | P50052 | Type-2 angiotensin II receptor (Angiotensin II type-2 receptor) (AT2 receptor) | 7 | HypertensionNeuropathySecondary hypertension | Clinical-translation mediationImmune mediationReceptor-signaling mediation | 1 | 0.25 | |||
| AMGO1 | Q86WK6 | Amphoterin-induced protein 1 (AMIGO-1) (Alivin-2) | Predicted membrane proteinsTransporters | 1 | Adhesion and uptake mediationFusion and delivery mediation | 1 | 0.25 | |||
| AMPE | Q07075 | Glutamyl aminopeptidase (EAP) (EC 3.4.11.7) (Aminopeptidase A) (AP-A) (Differentiation antigen gp160) (CD antigen CD249) | CD markersEnzymesPlasma proteins | 1 | Hypertension | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 1 | 0.25 | ||
| ANO5 | Q75V66 | Anoctamin-5 (Gnathodiaphyseal dysplasia 1 protein) (Transmembrane protein 16E) | Disease related genesHuman disease related genesPotential drug targets | 8 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.25 | |||
| ANPRC | P17342 | Atrial natriuretic peptide receptor 3 (Atrial natriuretic peptide clearance receptor) (Atrial natriuretic peptide receptor type C) (ANP-C) (ANPR-C) (NPR-C) | Disease related genesPredicted intracellular proteinsPredicted membrane proteins | 1 | Heart failure | Clinical-translation mediationImmune mediationMetabolism mediation | 1 | 0.25 | ||
| APCD1 | Q8J025 | Protein APCDD1 (Adenomatosis polyposis coli down-regulated 1 protein) | 1 | Receptor-signaling mediation | 1 | 0.25 | ||||
| AT1A3 | P13637 | Sodium/potassium-transporting ATPase subunit alpha-3 (Na(+)/K(+) ATPase alpha-3 subunit) (EC 7.2.2.13) (Na(+)/K(+) ATPase alpha(III) subunit) (Sodium pump subunit alpha-3) | Disease related genesEnzymesHuman disease related genes | 10 | Clinical-translation mediationFusion and delivery mediation | 1 | 0.25 | |||
| AT1B1 | P05026 | Sodium/potassium-transporting ATPase subunit beta-1 (Sodium/potassium-dependent ATPase subunit beta-1) | Metabolic proteinsPredicted intracellular proteinsPredicted membrane proteins | 1 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.25 | |||
| ATRN | O75882 | Attractin (DPPT-L) (Mahogany homolog) | Plasma proteinsPredicted membrane proteinsPredicted secreted proteins | 1 | Other mediation | 1 | 0.25 | |||
| AVR2B | Q13705 | Activin receptor type-2B (EC 2.7.11.30) (Activin receptor type IIB) (ACTR-IIB) | Cancer-related genesDisease related genesEnzymes | 1 | Nervous system paraneoplastic/autoimmune disorder | Clinical-translation mediationFusion and delivery mediationImmune mediation | 1 | 0.25 | ||
| BST1 | Q10588 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 (EC 3.2.2.6) (ADP-ribosyl cyclase 2) (Bone marrow stromal cell antigen 1) (BST-1) (Cyclic ADP-ribose hydrolase 2) (cADPR hydrolase 2) (CD antigen CD157) | CD markersEnzymesFDA approved drug targets | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 1 | 0.25 | ||||
| BTLA | Q7Z6A9 | B- and T-lymphocyte attenuator (B- and T-lymphocyte-associated protein) (CD antigen CD272) | CD markersPredicted membrane proteinsPredicted secreted proteins | 1 | Lupus erythematosusSjogren syndromeSolid tumour/cancer | Clinical-translation mediationImmune mediation | 1 | 0.25 | ||
| CA2D1 | P54289 | Voltage-dependent calcium channel subunit alpha-2/delta-1 (Voltage-gated calcium channel subunit alpha-2/delta-1) [Cleaved into: Voltage-dependent calcium channel subunit alpha-2-1; Voltage-dependent calcium channel subunit delta-1] | FDA approved drug targetsPlasma proteinsPredicted intracellular proteins | 1 | Anxiety disorderCardiovascular diseaseChronic obstructive pulmonary disease | Clinical-translation mediationFusion and delivery mediation | 1 | 0.25 | ||
| CAD10 | Q9Y6N8 | Cadherin-10 (T2-cadherin) | Predicted membrane proteins | 1 | Adhesion and uptake mediationFusion and delivery mediationReceptor-signaling mediation | 1 | 0.25 |